Introduction {#s1}
============

The regenerative capacity of adult skeletal muscle is endowed in a population of *Pax7*-expressing resident stem cells called satellite cells (SCs) ([@bib5]). Genetic studies utilizing lineage labeling, as well as cell ablation, have established that *Pax7*-expressing SCs are essential for various aspects of skeletal muscle regeneration ([@bib37]; [@bib25]). At homeostasis, SCs reside in a quiescent state at the interface between skeletal muscle fibers (myofibers) and the surrounding basal lamina ([@bib5]). In response to degenerative stimuli, SCs activate and undergo proliferative expansion, providing myogenic progenitors (MPs) necessary for myofiber regeneration ([@bib5]). Skeletal muscle regeneration requires a balance between SC/MP amplification and terminal myogenic commitment in order to efficiently form multinucleated myofibers ([@bib5]). Moreover, there is evidence that this balance is compromised in aging skeletal muscle, where changes in SC function and their surrounding environment occur, yielding defective progenitors and stem cells ([@bib9]; [@bib40]; [@bib2]; [@bib4]). Therefore, elucidating factors that regulate SC and derived MP fate is critical in order to develop interventions to combat aged skeletal muscle regenerative decline, in which these cells are lost.

Transforming growth factor beta (TGFβ) superfamily signaling is crucial for the renewal and maintenance of various tissue-specific stem cell populations ([@bib35]). Superfamily ligands include TGFβs, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), Activins, and Myostatin. These ligands bind to transmembrane type II receptors with differing specificities. This association leads to the eventual formation of transmembrane complexes composed of type I (activin-like kinases, ALKs) and type II receptor homodimers ([@bib27]). The formation of these complexes triggers the phosphorylation of receptor SMADs (R-SMADs). The R-SMADs associated with TGFβ/Activin/Inhibin and BMP ligands are SMAD2/3 and SMAD1/5/8 respectively. Phosphorylated R-SMADs, associated with the cofactor SMAD4, accumulate in the nucleus, where together with chromatin modifiers and other transcriptional co-factors they promote the expression of target genes. Depending on cell type and context, the TGFβ superfamily pathways regulate many cellular processes including differentiation, renewal, quiescence, and apoptosis ([@bib35]; [@bib28]). In aged regenerating skeletal muscle, TGFβ superfamily signaling is widely considered to be abnormally elevated, and is thought to inhibit SC activation and terminal myogenic differentiation ([@bib22]; [@bib43], [@bib44]). However, it has also been proposed that during regeneration TGFβ superfamily ligands may enable SC and MP expansion ([@bib33]; [@bib39]).

Smad4 is recognized as the canonical cofactor for TGFβ superfamily signaling and was initially identified as a tumor suppressor in pancreatic cancer ([@bib26]; [@bib30]; [@bib20]; [@bib32]). Loss-of-function *SMAD4* mutations lead to familial juvenile polyposis, which can be associated with hereditary hemorrhagic telangiectasia, and aggressive forms of various cancers ([@bib26]; [@bib1]). In myogenic culture systems derived from immortalized cell lines or using sequential pre-plate techniques, knockdown of Smad4 promotes myogenic differentiation ([@bib15]; [@bib33]). Furthermore, global reduction of expression through direct intramuscular injection of Smad4 siRNAs or viral vectors with Smad4 shRNAs into injured mouse skeletal muscle can promote the formation of larger regenerated muscle fibers relative to controls ([@bib15]; [@bib24]). However, given that multiple non-myogenic cell types, such as inflammatory cells and fibro/adipogenic progenitors, also contribute to SC and MP fate decisions during skeletal muscle regeneration; It is unclear which cellular mechanisms promote hypertrophy of regenerated myofibers with non-targeted Smad4 loss. In contrast, specific loss of Smad4 in MPs compromises myogenic differentiation during embryonic skeletal muscle development ([@bib18]). Additionally, consistent with the critical role for Smad4 in stem and progenitor cell function, targeted deletion of Smad4 in hematopoietic, hair follicle, and neural stem and derived progenitor cell populations leads to their depletion during homeostasis and regeneration ([@bib21]; [@bib46]; [@bib29]). Moreover, targeted loss of Smad4 in myofibers leads to modest deterioration during growth and aggravation of denervation-induced atrophy in adults ([@bib38]). Recently, gain-of-function *SMAD4* mutations that prevent ubiquitination and subsequent degradation have been identified as the cause of the rare developmental disorder Myhre syndrome in humans ([@bib6]; [@bib23]). Patients with Myhre syndrome are characterized by short stature, various musculoskeletal abnormalities, and hypertrophied musculature ([@bib6]; [@bib23]). Although Smad4 clearly has crucial roles in skeletal muscle and tissue-specific stem and progenitor cell biology, to date no studies have explicitly examined whether or not there is a cell-autonomous requirement for Smad4 in SCs and derived MPs during skeletal muscle regeneration.

In this study we show, in comparison to adult, evidence of failure to induce *Smad4* expression in aged SCs and MPs during skeletal muscle regeneration. In order to examine the consequences of cell-specific Smad4 loss, we utilized transgenic mice expressing tamoxifen-inducible Cre recombinase under the control of *Pax7* regulatory elements to perform targeted deletion of Smad4 in SCs. We found that specific disruption of Smad4 in adult SCs resulted in insufficient SC and derived MP amplification, which was accompanied by severe deficiencies in adult skeletal muscle regeneration. Unexpectedly, with specific loss of Smad4 in aged SCs in an environment of presumably high TGFβ activity, aged skeletal muscle regeneration was not improved.

Results {#s2}
=======

Smad4 expression is reduced in aged SCs and myogenic cells during regeneration {#s2-1}
------------------------------------------------------------------------------

Deficiencies in aged skeletal muscle regeneration reflect in part a failure or delay of SC or SC-derived MP expansion due to multiple factors. These factors include impaired activation, premature terminal fate commitment, and the occurrence of senescence and apoptosis ([@bib40]). Since SMAD-dependent signaling and target genes such as *Id1* have been implicated in the regulation of the terminal fate and amplification of SC and MP populations ([@bib33]; [@bib34]; [@bib10]), we examined the expression of *Smad4* and *Id1* in SCs and MPs from regenerating adult and aged skeletal muscles. Initially, we employed previously characterized flow cytometric analysis to examine age-related modification of SMAD4 protein levels in SCs and MPs (Lin-, Sca1-, ITGA7+) isolated from adult and aged, uninjured and regenerating skeletal muscle. Regenerating muscle was examined at five days post injury (5dpi), a time point when new myofibers are rapidly forming through the expansion, differentiation, and fusion of SC-derived myogenic cells ([@bib31]; [@bib11]; [@bib3]; [@bib16]). To induce skeletal muscle regeneration, a barium chloride (BaCl~2~) solution was directly injected into tibialis anterior (TA) muscles, which is an established model of skeletal muscle degeneration and regeneration ([@bib31]). Relative to SCs from adult uninjured TAs, an approximately 2.5-fold increase in SMAD4 protein was observed in SCs and MPs isolated from adult 5dpi TA muscles ([Figure 1A and C](#fig1){ref-type="fig"}). In contrast, SMAD4 induction was not detected in SCs and MPs isolated from aged 5dpi relative to uninjured TA muscles ([Figure 1B and C](#fig1){ref-type="fig"}). To further substantiate these findings, we conducted RTqPCR analysis of *Smad4* expression as well as the SMAD-target *Id1,* the loss of which is associated with deficiencies in skeletal muscle regeneration ([@bib10]). Both *Smad4* and *Id1* expression were higher in SCs and MPs from adult when compared to those from aged 5dpi TAs ([Figure 1D and E](#fig1){ref-type="fig"}). We were unable to obtain consistent Ct values in the detectable range (\<36) for *Smad4* or *Id1* in SCs from uninjured skeletal muscle indicative of low to negligible expression (data not shown). Therefore, a feature of age-related regenerative decline is the loss of Smad4 induction in SCs and MPs.10.7554/eLife.19484.003Figure 1.Loss of Smad4 expression in aged satellite cells and myogenic progenitors during muscle regeneration.Representative profiles of SMAD4 protein levels by flow cytometric analysis in SCs and MPs isolated from C57BL6 (**A**) adult and (**B**) aged uninjured and 5-day post injured (5dpi) (TA) muscles. (**C**) Quantification of SMAD4 protein levels in adult and aged SCs and MPs from uninjured and 5dpi TA muscles. (**D**) Quantification of *Smad4* expression in FACs-sorted SCs and MPs isolated from 5dpi adult and aged TA muscles. (**E**) Quantification of SMAD target *Id1* expression in FACs-sorted SCs and MPs isolated from 5dpi adult and aged TA muscles. N = 4 mice, for (**C**) \*p\<0.05 ANOVA and Fisher's test, (**D**) and (**E**) \*p\<0.05 t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.003](10.7554/eLife.19484.003)

Smad4 loss severely impairs SC clonal growth and proliferative potential {#s2-2}
------------------------------------------------------------------------

To begin investigating the consequences of Smad4 loss in adult SCs, *Smad4^flox/flox^* mice were bred with mice expressing a tamoxifen-inducible Cre under the control of *Pax7* regulatory elements (*Pax7^+/CreERT^*), enabling satellite cell-specific Smad4 disruption. To characterize Smad4 loss in *Pax7^+/CreERT^; Smad4^flox/flox^* (P7:S4KO) and *Pax7^+/+^; Smad4^flox/flox^* (Ctl) animals, adult mice were administered tamoxifen (Tmx), SCs and MPs from 5dpi TAs were prospectively isolated, and the expression of *Smad4* and the SMAD-target *Id1* were interrogated ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As a validation of successful deletion, flow cytometric analysis revealed that SMAD4 protein induction fails to occur in P7:S4KO SCs from 5dpi relative to uninjured skeletal muscles in comparison to the induction seen in Ctl muscles ([Figures 2A,B and C](#fig2){ref-type="fig"}). As expected, we also observed a reduction in *Smad4* and *Id1* mRNA levels in P7:S4KO when compared to Ctl SCs and MPs from 5dpi TAs ([Figure 2D and E](#fig2){ref-type="fig"}). We have also previously demonstrated a very high efficiency of *Pax7^CreERT ^*recombination in adult SCs ([@bib25]). Therefore, both Smad4 expression and function are efficiently lost in P7:S4KO SCs and MPs.10.7554/eLife.19484.004Figure 2.Disruption of Smad4 expression in P7:S4KO satellite cells and myogenic progenitors during muscle regeneration.Representative profiles of SMAD4 protein levels by flow cytometric analysis in SCs and MPs isolated from adult (**A**) Ctl and (**B**) P7:S4KO uninjured and 5dpi TA muscles. (**C**) Quantification of SMAD4 protein levels by flow cytometry of Ctl and P7:S4KO SCs and MPs from uninjured and 5dpi TA muscles. (**D**) Quantification of *Smad4* expression in FACs-sorted SCs and MPs isolated from 5dpi Ctl and P7:S4KO TA muscles. (**E**) Quantification of SMAD target *Id1* mRNA levels in FACs-sorted SCs and MPs isolated from 5dpi Ctl and P7:S4KO TA muscles. N = 4 mice, for (**C**) \*p\<0.05 to Ctl, \*\*p\<0.05 Adult Ctl ANOVA and Fisher's test, for (**D**) and (**E**) \*p\<0.05 t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.004](10.7554/eLife.19484.004)10.7554/eLife.19484.005Figure 2---figure supplement 1.Gating of control and P7:S4KO SCs for intracellular protein analysis.Representative flow cytometry plots of Ctl and P7:S4KO SCs used to examine SMAD4 protein levels in [Figure 2](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.005](10.7554/eLife.19484.005)

Previous studies have shown that knockdown of Smad4 or TGFβ superfamily ligand supplementation in myogenic cells is able to promote or impair terminal myogenic commitment, respectively ([@bib33]; [@bib15]; [@bib24]; [@bib44]). To examine the terminal myogenic fate decisions of Smad4-deficient SCs, FACs-purified adult P7:S4KO and Ctl SCs and MPs were cultured for 96 hr in plating media (10% horse serum, FGF2, DMEM), and supplemented with vehicle, TGFβ1, or BMP4 ligands ([@bib9], [@bib8]; [@bib47]). Based on immunofluorescence analysis, all cells regardless of genotype or supplementation were labeled by either Pax7 (SC renewal marker) or Myogenin (terminal myogenic commitment marker) ([Figure 3A](#fig3){ref-type="fig"}). Consistent with previous reports, both TGFβ1 and BMP4 supplementation led to a lower proportion of Ctl SC-derived cells that were Myogenin-positive ([Figure 3C](#fig3){ref-type="fig"}) ([@bib33]). Notably, cultures derived from P7:S4KO SCs contained a significantly lower proportion of Pax7+ cells; However, we observed a higher proportion of Myogenin+ cells compared to Ctl, regardless of supplementation ([Figure 3B and C](#fig3){ref-type="fig"}). We subsequently tested whether the enhanced terminal myogenic commitment observed in P7:S4KO cultures was associated with greater myogenic fusion and formation of immature multinucleated muscle fibers (myotubes). To achieve this, SCs were cultured at high density (10,000 cells/well) to ensure adequate numbers of fusion-competent MPs. Cultures were then immunostained with pan anti-skeletal muscle myosin antibody to visualize myotubes ([Figure 3D](#fig3){ref-type="fig"}). In accordance with an increased propensity to differentiate, quantification of nuclei within skeletal muscle myosin-expressing cells (fusion index) revealed this parameter to be \~two fold greater in P7:S4KO compared to Ctl myotubes ([Figure 3E](#fig3){ref-type="fig"}).10.7554/eLife.19484.006Figure 3.Enhanced terminal myogenic commitment in P7:S4KO satellite cells and myogenic progenitors.(**A**) Representative images of Pax7 (red), Myogenin (green), and DAPI (blue) immunofluorescence in FACs-sorted adult Ctl or P7:S4KO 96 hr SC cultures (plated at 4000 cells/well) treated with vehicle, TGFβ1, or BMP4. (**B**) Quantification of Pax7 immunofluorescence in Ctl and P7:S4KO FACs-sorted SC cultures. (**C**) Quantification of Myogenin immunofluorescence in Ctl and P7:S4KO FACs sorted SC cultures. (**D**) Representative images of Pax7 (red), skeletal muscle myosin (green), and DAPI (blue) immunofluorescence in adult FACs-sorted Ctl or P7:S4KO myotube cultures (plated at 10000 cells/well). (**E**) Quantification of fusion index; myonuclei/myosin+ cell. N = 3 cultures, For (**B**) and (**C**) \*p\<0.05 significant to Ctl, \*\*p\<0.05 significant to vehicle Ctl, ANOVA Fishers test, for (**E**) \*p\<0.05 t-test, scale = 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.006](10.7554/eLife.19484.006)10.7554/eLife.19484.007Figure 3---figure supplement 1.Modulations in FGFR and FGF expression following SC-specific Smad4 loss in adult mice.Quantification of (**A**) *Fgf1,* (**B**) *Fgf2*, (**C**) *Fgf6,* (**D**) *Fgfr1, and* (**E**) *Fgfr4* expression in FACs-purified adult SCs and MPs cultured for five days. N = 3 mice, \*p\<0.05 t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.007](10.7554/eLife.19484.007)

Specific Smad4 deletion in embryonic tongue MPs leads to impaired myogenic differentiation attributed to reduced *Fgfr4* and *Fgf6* expression ([@bib18]). Given that we observed enhanced terminal myogenic commitment in culture, we then examined the expression levels of pertinent FGF ligands and receptors in five day cultures from Smad4-deleted adult SCs and derived MPs. Although we observed reductions in *Fgfr4* and *Fgf6* expression, we also identified a decrease in *Fgfr1* and an induction of *Fgf2* expression ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Therefore, unlike what is seen in embryonic MPs from tongue muscle, loss of *Fgf6* and *Fgfr4* expression as a result of specific Smad4 disruption in adult SCs is associated with increased terminal commitment, reduced *Fgfr1* and elevated *Fgf2* expression.

Next, we assessed the proliferative potential of Ctl and P7:S4KO SC cultures. FACs-purified adult P7:S4KO and Ctl SCs and MPs were cultured in plating media for 72 hr, and pulsed with the thymidine analog EdU for the last 4 hr ([@bib41]). The vast majority of cells in 72 hr cultures, regardless of genotype, were labeled by the myogenic fate markers Pax7 or MyoD ([Figures 4A,C and D](#fig4){ref-type="fig"}). In comparison to Ctl, the proportion of P7:S4KO cells that had incorporated EdU was significantly reduced ([Figure 4B](#fig4){ref-type="fig"}). We performed further immunofluorescence analysis of MyoD and Pax7 labeling to assess the fate of Ctl and P7:S4KO SCs in 72 hr cultures ([Figure 4C](#fig4){ref-type="fig"}). Although no difference was observed in the proportion of cells that were Pax7+/MyoD-, P7:S4KO cultures displayed higher percentages of Pax7-/MyoD+ cells and a lower proportion of Pax7+/MyoD+ cells ([Figure 4D](#fig4){ref-type="fig"}). Collectively, these observations provide additional evidence that specific disruption of Smad4 in SCs promotes terminal myogenic commitment, which is associated with reduced proliferative potential.10.7554/eLife.19484.008Figure 4.Reduced proliferation in P7:S4KO satellite cells and myogenic progenitors.(**A**) Representative images of MyoD (green), EdU (grey), and DAPI (blue) immunofluorescence of FACs-sorted adult Ctl or P7:S4KO 72 hr SC cultures pulsed with EdU for the last 4 hr. (**B**) Quantification of the proportion of cells that are EdU+. N = 3 cultures, \*p\<0.05 t-test,scale = 50 μm. (**C**) Representative images of MyoD (green), Pax7 (red), and DAPI (blue) immunofluorescence of FACs-sorted adult Ctl or P7:S4KO 72 hr SC cultures, scale = 50 μm. (**D**) Quantification of the proportion of cells that are Pax7+ and/or MyoD+. N = 3 cultures, \*p\<0.05 t-test. (**E**) Representative images of Crystal Violet-stained 7-day cultures of FACs-sorted adult Ctl or P7:S4KO myogenic cells plated at clonal density (10 cells/well), scale = 200 μm. (**F**) Quantification of cell growth. N = 96 cultures, \*p\<0.05 t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.008](10.7554/eLife.19484.008)

To further assess these cellular mechanisms, we sought to determine the consequences of Smad4 loss on SC clonal growth potential. FACs-purified adult Ctl and P7:S4KO SCs were sorted directly into 96 well plates at 10 cells per well, cultured for seven days, and stained with Crystal Violet to enable counting with conventional light microscopy ([Figure 4E](#fig4){ref-type="fig"}). Consistent with our observation of reduced proliferative potential, we found the clonal growth potential of P7:S4KO SCs to be significantly reduced compared to Ctl ([Figure 4F](#fig4){ref-type="fig"}).

Loss of Smad4 in adult SCs impairs progenitor expansion during regeneration {#s2-3}
---------------------------------------------------------------------------

To initially examine SC fate in vivo, adult P7:S4KO and Ctl 5dpi TA muscles were processed to assess Pax7+ SC proliferation and number. To identify proliferating Pax7+ SCs at 5dpi, a pulse of the thymidine analog BrdU was i.p. administered at 2 hr prior to sacrifice. Quantification of the proportion of BrdU+/Pax7+ cells revealed a significant reduction in proliferating as well as total Pax7+ SCs in 5dpi P7:S4KO muscles ([Figure 5A--C](#fig5){ref-type="fig"}). Additionally, we examined the expression of cell cycle inhibitors *Cdkn1a* (p21), *Cdkn1b* (p27), and *Cdkn2a* (p16). No induction in the expression of cell cycle inhibitors was observed in adult P7:S4KO SCs and MPs isolated by FACs from 5dpi TAs ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Furthermore, no significant difference was observed between P7:S4KO and Ctl SC number in uninjured TAs 21 days after Tmx treatment ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Therefore, the loss of SCs in P7:S4KO 5dpi TAs does not reflect initial declines in Pax7+ SCs upon recombination at homeostasis.10.7554/eLife.19484.009Figure 5.Smad4 disruption induces loss of proliferating and total satellite cell number during muscle regeneration.(**A**) Representative images of Pax7 (red), BrdU (green), DAPI (blue) and Laminin (grey) immunofluorescence in adult 5dpi Ctl and P7:S4KO TA muscle sections. (**B**) Quantification of the proportion of BrdU+ Pax7+ cells in adult 5dpi Ctl and P7:S4KO TA muscle sections. (**C**) Quantification of Pax7+ cells in adult 5dpi Ctl and P7:S4KO TA muscle sections. N = 4 mice, \*p\<0.05 t-test, scale = 50 μm. Pax7+ cells (white arrows) and Pax7+BrdU+ (yellow arrows).**DOI:** [http://dx.doi.org/10.7554/eLife.19484.009](10.7554/eLife.19484.009)10.7554/eLife.19484.010Figure 5---figure supplement 1.Smad4 disruption does not induce *Cdkn1a*, *Cdkn1b*, or *Cdkn2a* expression in SCs and MPs sorted from adult regenerating TA muscle.Quantification of (**A**) *Cdkn1a* (p21) (**B**) *Cdkn1b* (p27), and (**C**) *Cdkn2a* (p16) expression in SCs and MPs FACs-sorted from adult 5dpi Ctl and P7:S4KO TA muscles. N = 3 mice, \*p\<0.05 t-test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.010](10.7554/eLife.19484.010)10.7554/eLife.19484.011Figure 5---figure supplement 2.Smad4 disruption does not induce loss of Pax7+ SCs in uninjured TA muscles.(**A**) Representative images of Pax7 (red), DAPI (blue) and Laminin (grey) immunofluorescence of adult uninjured Ctl and P7:S4KO TA muscle sections. (**B**) Quantification of Pax7+ cells in adult uninjured Ctl and P7:S4KO TA muscle sections. N = 4 mice, scale = 50 μm. Pax7+ cells (white arrows).**DOI:** [http://dx.doi.org/10.7554/eLife.19484.011](10.7554/eLife.19484.011)

To examine MP number and fate, adult Ctl and P7:S4KO 5dpi muscle sections were processed for the detection of MyoD and active Caspase-3 (aCasp, apoptosis marker) by immunofluorescence ([Figure 6A](#fig6){ref-type="fig"}). Consistent with the declines seen in Pax7+ SC proliferation and number, we found that MyoD+ cell number was reduced in P7:S4KO 5dpi muscles ([Figure 6C](#fig6){ref-type="fig"}). Although we observed a significant reduction in MyoD+ cells, the proportion of MPs that were aCasp+ was similar in both Ctl and P7:S4KO 5dpi muscles ([Figure 6D](#fig6){ref-type="fig"}). Therefore, SC-specific Smad4 disruption leads to impaired SC and MP amplification that does not coincide with heightened cell death.10.7554/eLife.19484.012Figure 6.Smad4 disruption enhances terminal myogenic commitment during muscle regeneration.(**A**) Representative images of active Caspase 3 (aCasp, green), MyoD (red), DAPI (blue), and Laminin (grey) immunofluorescence of adult 5dpi Ctl and P7:S4KO TA muscle sections. MyoD+ cells (white arrows) and MyoD+aCasp+ (yellow arrows). (**B**) Representative images of Myogenin (MyoG, green), Pax7 and MyoD (red), DAPI (blue) and Laminin (grey) immunofluorescence of adult 5dpi Ctl and P7:S4KO TA muscle sections. (**C**) Quantification of MyoD+ cells in 5dpi Ctl and P7:S4KO TA muscle sections. (**D**) Quantification of the proportion of aCasp+ MyoD+ cells in 5dpi Ctl and P7:S4KO TA muscle sections. (**E**) Quantification of the proportion of MyoG+ Pax7 and MyoD+ cells in 5dpi Ctl and P7:S4KO TA muscles. Pax7 and MyoD+ cells (white arrows) and Pax7 and MyoD+ MyoG+ (yellow arrows) MyoG+ (green arrows). N = 4 mice, \*p\<0.05 t-test, scale = 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.012](10.7554/eLife.19484.012)

To determine if reduced SC and MP amplification upon Smad4 loss coincides with an increased propensity for terminal commitment in vivo, adult Ctl and P7:S4KO 5dpi muscle sections were processed for the immunofluorescent detection of Pax7 and MyoD together (Pax7+MyoD) and Myogenin (MyoG), recognized with separate fluorescent-conjugated secondary antibodies ([Figure 6B](#fig6){ref-type="fig"}). The examination of Pax7/MyoD+ cells with Myogenin labeling enables the detection of total myogenic cells and based on the proportion that are Myogenin+, the extent of terminal myogenic commitment can be determined. Consistent with our SC-derived culture data, we found that a significantly higher proportion of myogenic cells were terminally committed in P7:S4KO 5dpi muscles ([Figure 6E](#fig6){ref-type="fig"}). Therefore, reduced SC and MP amplification resulting from Smad4 loss coincides with an increased drive toward terminal myogenic commitment during muscle regeneration.

SC-specific Smad4 loss severely impairs skeletal muscle regeneration at all ages {#s2-4}
--------------------------------------------------------------------------------

To assess the consequences of Smad4 deletion on proper muscle regeneration, we examined the size of Ctl and P7:S4KO 5dpi regenerated myofibers identified with embryonic Myosin Heavy Chain (eMyHC, marker of recent regeneration) and Laminin staining by immunofluorescence ([Figure 7A](#fig7){ref-type="fig"}). In agreement with what would be expected given the impairment in SC-derived MP amplification, the size (cross-sectional area) of eMyHC-positive myofibers was reduced in adult 5dpi regenerated skeletal muscles following SC-specific Smad4 disruption ([Figure 7C](#fig7){ref-type="fig"}).10.7554/eLife.19484.013Figure 7.Smad4 disruption in satellite cells impairs skeletal muscle regeneration.Representative images of embryonic Myosin Heavy Chain (eMyHC, green), DAPI (blue) and Laminin (grey) immunofluorescence of 5dpi Ctl and P7:S4KO (**A**) adult and (**B**) aged TA muscle sections. (**C**) Quantification of average eMyHC+ regenerated myofiber size in 5dpi adult and aged Ctl and P7:S4KO TA muscles. N = 4 mice, 250--300 myofibers. \*p\<0.05 ANOVA Fishers test, scale = 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.013](10.7554/eLife.19484.013)10.7554/eLife.19484.014Figure 7---figure supplement 1.Smad4 disruption reduces *Smad4* and the SMAD target *Id1* expression in adult and aged SCs and MPs sorted from regenerating TA muscle.Quantification of (**A**) *Smad4,* (**B**) *Id1* and (**C**) *Cdkn2a* (p16) mRNA levels in SCs and MPs FACs-sorted from 5dpi adult and aged Ctl and P7:S4KO TA muscle sections. N = 3 mice, \*p\<0.05 ANOVA Fishers test.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.014](10.7554/eLife.19484.014)

In aged regenerating skeletal muscle, elevated TGFβ activity is thought to impair SC and myogenic progenitor amplification ([@bib7]; [@bib36]). Furthermore, non-specific knockdown of Smad4 through siRNAs or viral delivery of shRNAs to regenerating aged skeletal muscle promotes myofiber hypertrophy ([@bib15]; [@bib24]). Therefore, we sought to examine whether specific disruption of Smad4 in aged SCs could promote aged skeletal muscle regeneration, presumably in an environment of high TGFβ ligand activity, suggesting that the implications of signaling loss could differ from results observed in adult mice. To test this hypothesis, P7:S4KO and Ctl mice were aged to 22 months and treated with Tmx. Thereafter, a TA muscle was degenerated with intramuscular injection of BaCl~2~, and subsequently allowed to regenerate for five days. In accordance with Smad4 disruption in adult mice, expression of *Smad4* and the SMAD-target *Id1* was reduced in FACs-isolated SCs and MPs from aged P7:S4KO 5dpi TAs, validating efficient and similar Cre-mediated Smad4 deletion at both ages ([Figure 7---figure supplement 1A and B](#fig7s1){ref-type="fig"}). As described elsewhere, aged SCs displayed elevated expression of *Cdkn2a* (p16), however the extent of increased expression did not differ in response to Smad4 disruption ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) ([@bib41]; [@bib3]; [@bib11]; [@bib7]). Based on quantification of regenerated eMyHC-positive myofiber size, specific loss of Smad4 in aged SCs did not promote aged regeneration ([Figure 7B and C](#fig7){ref-type="fig"}).

To determine if persisting regenerative deficits could be detected in aged and adult P7:S4KO mice, additional TA muscles were analyzed at 14 days following BaCl~2~ injury, a timepoint at which regeneration should essentially be complete. Regardless of genotype, uninjured TAs demonstrated similar age-related myofiber atrophy ([Figure 8A,B and C](#fig8){ref-type="fig"}). Examination of 14dpi TAs revealed that, at all ages, insufficient muscle regeneration persisted following SC-specific Smad4 loss ([Figure 8B and D](#fig8){ref-type="fig"}). Collectively, these data identify Smad4 as a critical muscle stem cell regulator, maintaining the appropriate balance between SC-derived MP amplification and terminal commitment during aged and adult skeletal muscle regeneration.10.7554/eLife.19484.015Figure 8.Smad4 disruption in satellite cells leads to persistent deficits in skeletal muscle regeneration.Representative images of H and E-stained uninjured and 14dpi, and Sirius Red-stained 14dpi (**A**) adult and (**B**) aged TA muscle sections. Quantification and frequency distribution of (**C**) uninjured and (**D**) 14dpi myofiber size in adult and aged Ctl and P7:S4KO TA muscles. N = 4 mice, 700--900 myofibers. For (**C**) \*p\<0.05 to Adult, for (**D**) \*p\<0.05 to Ctl, \*\*p\<0.05 to Adult Ctl, ANOVA Fisher's test, scale = 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.19484.015](10.7554/eLife.19484.015)

Discussion {#s3}
==========

Here we find Smad4 to be a factor that is normally induced in adult, but lost in aged, SCs and MPs in regenerating muscles. Furthermore, we demonstrate that in an inducible mouse model driving specific loss of Smad4 in SCs, a decline in the number of proliferating Pax7+ SCs and MPs, and consequently severe deficits in skeletal muscle regeneration are experienced regardless of age. Several studies have specifically manipulated components of TGFβ superfamily signaling in myogenic progenitors and SCs ([@bib17]; [@bib18]; [@bib19]). However, until now, no reports have examined the cell-autonomous roles of Smad4, the common cofactor for all branches of canonical TGFβ superfamily signaling, in adult or aged Pax7+ SCs and determined the subsequent consequences on skeletal muscle regeneration.

Consistent with previous reports, Smad4 disruption did promote myogenic terminal commitment ([@bib15]; [@bib33]; [@bib24]). However, declines in proliferating SCs and MPs during regeneration were also observed. Myofibers are multinucleated cells formed by the fusion of many terminally committed myogenic cells. Therefore, the progression to the formation of mature multinucleated myofibers can be impeded at multiple levels, including impaired myogenic differentiation and/or reduced MP amplification through a variety of mechanisms: inhibition of cell cycle entry, cell death, and/or premature terminal commitment ([@bib40]; [@bib5]). Given that we have detected differences in myogenic cell proliferation with no increased cell death or cell cycle inhibitor expression, we suspect that the reduced number of MPs in regenerating skeletal muscles following acute SC-specific Smad4 loss is likely due to a heightened propensity for terminal commitment. In contrast, specific disruption of Smad4 in embryonic mouse MPs, driven by *Myf5-Cre*, altered terminal myogenic commitment and myofiber formation in the tongue ([@bib18]). Intuitively, these divergent results could reflect differences in the intrinsic mechanisms that regulate SCs and MPs in response to the environments of embryonic tongue growth versus adult TA regeneration. Another possibility is that the *Myf5-Cre*, in addition to targeting the myogenic lineage, drives recombination in further resident cell populations with the capacity to directly or indirectly influence skeletal muscle growth and regeneration ([@bib19]). It will be of interest to determine in what manner specific disruption of Smad4 in other resident non-myogenic cell populations may influence adult or aged skeletal muscle regeneration. Although in adult Smad4 null SC cultures we observed reductions in *Fgf6* and *Fgfr4* expression similar to embryonic Smad4 deleted muscle, we also detected a robust induction of *Fgf2*. We have previously found that the presence of elevated levels of FGF2 in aged skeletal muscle is associated with a propensity for aged SCs to progress toward terminal fates ([@bib9]). Therefore, compensatory induction of FGF2 resulting from Smad4 loss may be a unique feature of adult SCs that drives terminal myogenic commitment, the mechanisms of which will require further investigation.

Previous work has shown that loss of BMP signaling induces premature terminal myogenic commitment, preventing SC and MP amplification ([@bib33]). Furthermore, Id1, which we found to be reduced in aged wildtype and adult P7:S4KO SCs and derived MPs, was identified as a SMAD target required for SC and MP amplification ([@bib33]). Indeed, through direct interactions Id1 can also promote Myogenin degradation ([@bib45]). Therefore, loss of Id1 in aged and P7:S4KO SCs and MPs during regeneration could potentially stabilize Myogenin and thus promote excessive terminal commitment that impedes myogenic cell amplification. Although we observe loss of *Smad4* and *Id1* expression, some reports have described the presence of elevated TGFβ and phospho-Smad activity in aged SCs and MPs from regenerating skeletal muscle ([@bib7]; [@bib36]). Although less characterized, TGFβ can function through non-canonical Smad4-independent pathways ([@bib13]; [@bib28]). For instance, pSmad3, which is elevated in aged SCs and MPs, also associates with Drosha in a Smad4-independent complex required for microRNA processing ([@bib12]). Studies examining keratinocyte differentiation have shown Iκβ kinase to be a critical regulator of signaling through Smad2/3 that is Smad4-independent ([@bib14]). Non-canonical TGFβ mediators such as TAK1 (TGFβ activated kinase 1) and the downstream target p38 are both shown to be elevated in aged myogenic cells ([@bib11]; [@bib3]; [@bib43]). Notably, heightened p38 activity in aged SCs hinders myogenic cell amplification through mechanisms that include promotion of terminal myogenic commitment ([@bib11]; [@bib3]). Collectively, it will be critical to determine if loss of Smad4 in aged and P7:S4KO SCs and MPs could impair myogenic cell amplification through promotion of multiple Smad4-independent pathways.

Although the TGFβ superfamily pathways are capable of influencing multiple cell types that contribute to the regeneration of skeletal muscle, few studies have examined specific inhibition of these pathways in adult or aged SCs and their derived progenitors. For example, it has been shown that SC-specific loss of Cripto, an inhibitor of Activin, Myostatin, and TGFβ signaling in myogenic cells, leads to smaller regenerated myofibers ([@bib17]). Additionally, genetic ablation of the BMP receptor *Alk3* in embryonic myogenic cells, utilizing *MyoD-Cre* and *Myf5-Cre* mice, was found to result in ineffective adult skeletal muscle regeneration, however this occurs primarily through mechanisms other than major dysfunction within the SC pool ([@bib19]). This conclusion was based primarily on the lack of observable depletion or dysfunction of *Alk3* null SCs in vivo or in culture, respectively, which is thought to occur due to stimulation of the expression of the related *Alk6* as a compensatory mechanism to maintain SC function ([@bib19]). In this study, we determined that inducible *Pax7*-driven loss of Smad4 impedes SC-derived myogenic proliferation and proper skeletal muscle regeneration. Further studies will be needed to determine in what way targeted disruption of Alk3, induced later in life, in adult or aged SCs may affect skeletal muscle regeneration at these ages, with potential compensation possibly being eliminated.

Although not specifically targeting SCs or MPs, intramuscular delivery of Smad4 siRNA or shRNA at later time points during regeneration has been shown to stimulate myofiber hypertrophy ([@bib15]; [@bib24]). Furthermore, utilizing miR-26 disruption to increase, and miR-431 mimics to decrease, *Smad4* expression at later timeponts during regeneration promotes myofiber atrophy and hypertrophy respectively ([@bib15]; [@bib24]). However, it is intuitive that since microRNAs often target many genes, the aforementioned manipulations likely do not alter *Smad4* expression alone. Therefore, it remains unclear whether the balance between myogenic progenitor expansion and terminal fate commitment could be manipulated to be beneficial to adult and aged muscle if cell-specific Smad4 loss was induced at different timepoints during regeneration or by alternative, more transient, means.

Here, we demonstrate that induction of Smad4 is compromised in aged SCs and myogenic cells during skeletal muscle regeneration. Disruption of Smad4 specifically in adult SCs leads to phenotypes observed in aged regenerating skeletal muscle including compromised proliferation and amplification of SC-derived MPs. Collectively, these data indicate that Smad4 function in SCs is essential for adult and aged skeletal muscle regeneration in the mouse. Moving forward, careful dissection of Smad4-mediated pathways and targets may yield novel factors that promote skeletal muscle genesis in the contexts of aging and disease.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

All procedures involving mice were carried out in accordance with guidelines set by the Animal Care and Use Committee at the University of Rochester. Adult (3--6 months) and aged (22--24 months) mice were housed in the animal facility with free access to standard rodent chow and water. All mouse strains were obtained from Jackson Laboratory (Bar Harbor, ME): C57BL/6J, *Pax7^CreER^* (017763), and *Smad4^flox/flox^* (017462). Aged C57BL6 mice were obtained from the National Institute on Aging. PCR genotyping was performed using protocols described by Quanta, with primer sequences and annealing temps provided by JAX. To induce Cre recombination, mice were injected i.p. with 100 μL of 20 mg/mL (\~60 μg/kg) tamoxifen (Tmx, Sigma-Aldrich, St. Louis, MO, T5648 in 90% Sigma corn oil/10% EtOH) for five consecutive days, with clearance for five days prior to injury. To examine Pax7+ SC numbers at homeostasis, muscles were harvested 21 days after Tmx administration. Tmx-injected *Pax7^+/+^;Smad4^flox/flox^* littermates in each cohort were used as controls.

Skeletal muscle injury {#s4-2}
----------------------

Mice were anesthetized with an i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) or by 1--3% isoflurane inhalation. Buprenorphine (0.1 mg/kg) was administered prior to the procedure and approximately every 12 hr as needed. The skin overlaying the tibialis anterior (TA) muscle was shaved and the TA was directly injected with a 1.2% solution of BaCl~2~ in normal saline. At five days post-injury, injured and contralateral (uninjured) TAs were collected. TAs collected for immunofluorescence were incubated at 4°C overnight in 30% sucrose prior to embedding in OCT and flash freezing.

Skeletal muscle primary cell isolation {#s4-3}
--------------------------------------

To obtain highly purified SCs and MPs, primary cells were isolated from regenerating and uninjured muscles as described previously ([@bib9]; [@bib36]). Hindlimb muscles were isolated and myofiber fragments were obtained by Type II Collagenase (Gibco, Carlsbad, CA) digestion, trituration, and multiple sedimentation. Mononucleated cells were liberated by further Type II Collagenase and Dispase (Gibco) digestion, trituration, sedimentation and filtration. Cells were stained with CD31, Sca1, CD45 (BD Biosciences, San Jose, CA, \#561410, \#562058, Biolegend, San Diego, CA, \#103132), and Integrin α7 (AbLab, Vancouver, Canada, clone R2F2) fluorescent-conjugated antibodies. Cells were collected using a FACSAria II Cell Sorter (BD Biosciences). Live SCs/MPs were isolated using forward and side scatter profiles, negative selection for DAPI, CD31/45 and Sca1, and positive selection for Integrin α7.

Intracellular flow cytometry {#s4-4}
----------------------------

Injured and contralateral uninjured TAs were digested as described above. SCs/MPs were identified by an alternate cell surface staining panel selecting for Integrin α7 and negatively selecting for CD31, CD45, and Sca1 (Biolegend \#102420, \#103132, \#108127). Cell fixation, permeabilization, and intracellular staining of Smad4 (Santa Cruz Biotechnology, Santa Cruz, CA, sc-7966 PE) using BD Fixation Buffer (\#554655) and BD Phosflow Perm Buffer III (\#558050) was carried out according to the BD Phosflow protocol. Analysis of cell surface and intraceullar staining was performed on an LSR II Flow Cytometer (BD Biosciences). Mean Fluorescent Intensity (MFI) was quantified with FlowJo software. Negative controls stained with all cell surface markers but not intracellular antibodies were analyzed to assess background staining. Negative control MFI was subtracted to obtain final MFI values.

FACs-purified SC/MP cultures {#s4-5}
----------------------------

FACs-purified SCs/MPs were plated at 4000 cells per well in eight-well Permanox chamber slides (Nunc, Rochester, NY) and cultured for five days in plating media (10% Horse Serum, 5 ng/mL FGF2, DMEM). The ligands TGFβ1 (10 ng/mL) and BMP4 (10 ng/mL), as well as DMSO vehicle (1 μL/mL), were added to cultures beginning on day 3. Cultures were immunostained for Pax7 and Myogenin to characterize P7:S4KO and Ctl terminal myogenic commitment. To assess myotube formation, FACs-purified SCs/MPs were plated at 10,000 cells per well and cultured for five days in plating media, ensuring sufficient cell density to promote fusion. Myotube cultures were immunostained for skeletal muscle myosin and DAPI to calculate fusion index (myonuclei per myosin-positive cell). To assess clonal cell growth, FACs-sorted SCs were plated at clonal density (10 cells per well in 96 well plates) and the number of Crystal Violet-stained cells present in each individual well was determined after seven days in culture.

Cell proliferation analysis {#s4-6}
---------------------------

In SC/MP cultures (plated at 5000 cells per well), proliferative capacity was assayed by EdU (5-ethynyl-2\'-deoxyuridine) incorporation using the Click-iT EdU Alexa Fluor 647 Imaging Kit (Molecular Probes, Carlsbad, CA, C10640). Cells were grown in basal media for 72 hr and incubated with EdU for the last 4 hr. EdU detection was performed according to manufacturer protocol and was followed by immunostaining for Pax7 and MyoD. In vivo cell proliferation in Ctl and P7:S4KO mice was assayed by immunostaining for Pax7, BrdU (5-bromo-2'-deoxyuridine), and Laminin after 250 μL of 2 mg/ml (\~15 μg/kg) BrdU (Sigma) was i.p. injected two hours prior to harvest of injured and contralateral uninjured TA muscles.

Immunofluorescence {#s4-7}
------------------

Dissected TA muscles were incubated overnight at 4°C in 30% sucrose, flash frozen, cryosectioned at 10 μm, and stored at −80°C prior to staining. Muscle sections were fixed for 3 min in 4% paraformaldehyde (PFA), and if needed, subjected to antigen retrieval: incubation in citrate buffer (10 mM sodium citrate, pH 6.0) in a steamer (Oster \#5712) for 15 min after 10 min preheating of buffer ([@bib25]; [@bib42]). Tissue sections were permeabilized with PBS-T (0.2% Triton X-100) for 10 min and blocked in 10% Normal Goat Serum (NGS; Jackson Immuno Research, West Grove, PA) in PBS-T for 30 min at room temperature. When mouse primary antibodies were used, sections were additionally blocked in 3% AffiniPure Fab fragment goat anti-mouse IgG(H+L) (Jackson Immuno Research) with 2% NGS in PBS at room temperature for 1 hr. Primary antibody incubation in 2% NGS/PBS was carried out at 4°C overnight or 2 hr at RT and sections were incubated with secondary antibodies in 2% NGS/PBS for 1 hr at RT. DAPI staining was used to label nuclei. All slides were mounted with Fluoromount-G (SouthernBiotech, Birmingham, AL). At least four sections from three slides were analyzed per sample. Immunocytochemistry was performed following the same protocol with the exception of the Fab blocking step. Sections and cells were imaged on a Zeiss Axio Observer A.1 microscope (Germany).

Skeletal muscle regeneration assay {#s4-8}
----------------------------------

Sections of TA muscles were harvested at five or 14 days post-injury from adult or aged Ctl and P7:S4KO mice. Regenerated skeletal muscles harvested five days after injury were immunostained with embryonic Myosin Heavy Chain (eMyHC) antibodies to label actively regenerating fibers and average cross-sectional area of 250--300 myofibers was quantified with ImageJ. Regenerated skeletal muscles harvested 14 days after injury were processed for H and E or Sirius Red staining. For H and E, flash-frozen sections were fixed for 3 min in 4% PFA, stained with Mayers Hematoxylin and Alcoholic Eosin Y, dehydrated, equilibrated with xylene and mounted using Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI). For Sirius Red staining, a Picrosirius Red stain kit (Polysciences, Warrington, PA) was utilized. Frozen sections were fixed for 1 hr at 56°C in Bouin's fixative, washed in water, stained for 1 hr in Picrosirius Red, washed in 1 M HCl, dehydrated, equilibrated and mounted. Bright-field images were collected with a Zeiss Axioskop 40 microscope. To obtain quantification of average cross-sectional area and frequency distribution of 14dpi regenerated fiber size, Myosin/Laminin immunostained TA sections were analyzed using ImageJ software.

RNA isolation and RT-qPCR {#s4-9}
-------------------------

RNA was isolated from sorted SCs/MPs, or sorted SC/MP 5-day cultures for FGF analysis using phase separation in Trizol (Invitrogen, Carlsbad, CA) followed by cleanup with the RNeasy Plus Minikit (Qiagen, Germany), according to manufacturer protocols. To prepare sorted cell RNA for RT-qPCR, first-strand complementary DNA was synthesized from \~50 ng of RNA using the SuperScript First-Strand cDNA Synthesis Kit (Invitrogen). RT-qPCR was performed on a Step One Plus Real Time PCR machine (Applied Biosystems, Carlsbad, CA) using Platinum SYBR Green qPCR SuperMix-UDG with ROX master mix (Invitrogen). Experiments were standardized to *Gapdh*. All reactions for RT-qPCR were performed using the following thermal cycler conditions: 50°C for 2 min, 95°C for 2 min, 40 cycles of a two-step reaction, denaturation at 95°C for 15 s, annealing at 60°C for 30 s. The following primers were used:

**Primer nameForward sequenceReverse sequence**GapdhAGGTCGGTGTGAACGGATTTGTGTAGACCATGTAGTTGAGGTCSmad4ACACCAACAAGTAACGATGCCGCAAAGGTTTCACTTTCCCCAId1CCTAGCTGTTCGCTGAAGGCCTCCGACAGACCAAGTACCACCdkn1a (p21)TCGCTGTCTTGCACTCTGGTGTCCAATCTGCGCTTGGAGTGATAGCdkn1b (p27)TCAAACGTGAGAGTGTCTAACCCGGGCCGAAGAGATTTCTGCdkn2a (p16)CGCAGGTTCTTGGTCACTGTTGTTCACGAAAGCCAGAGCGFgf1CCCTGACCGAGAGGTTCAACGTCCCTTGTCCCATCCACGFgf2GCGACCCACACGTCAAACTATCCCTTGATAGACACAACTCCTCFgf6CAGGCTCTCGTCTTCTTAGGCAATAGCCGCTTTCCCAATTCAFgfr1GCCTCACATTCAGTGGCTGAAGAGCACCTCCATTTCCTTGTCGGFgfr4TCCGACAAGGATTTGGCAGACCTGGCGGCACATTCCACAATCAC

Antibodies {#s4-10}
----------

The following antibodies were used: Mouse anti-Pax7 (1:100, Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA), rabbit or mouse anti-MyoD (1:250, Santa Cruz, sc-304 or BD Biosciences \#554130), rabbit anti-Myogenin (1:250, Santa Cruz, sc-576), mouse anti-embryonic Myosin Heavy Chain BF-45/F1.652 (1:40, Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA), rat anti-BrdU (1:250, Abcam, Cambridge, UK, ab6326), rabbit anti-Cleaved Caspase 3 (1:400, Cell Signaling, Beverly, MA, \#9664), rat or rabbit anti-Laminin (1:1000 or 1:1500, Sigma-Aldrich, L0663 or L9393), rabbit anti-skeletal muscle myosin (1:250, Sigma-Aldrich HPA1239), AlexaFluor 594-conjugated goat anti-mouse IgG (1:1500, Life Technologies, Carlsbad, CA, A-11032), AlexaFluor 488-conjugated goat anti-mouse IgG (1:1500, Life Technologies, A-11001), AlexaFluor 488-conjugated goat anti-rabbit IgG (1:1500, Life Technologies, A-11034), AlexaFluor 488-conjugated goat anti-rat IgG (1:1500, Life Technologies, A-11006), AlexaFluor 647-conjugated goat anti-rat IgG (1:1500, Life Technologies, A-21247), AlexaFluor 647-conjugated goat anti-rabbit IgG (1:1500, Life Technologies, A-21244).

Data analysis {#s4-11}
-------------

Immunofluorescent images were analyzed using ImageJ software. Results are presented as mean + SEM. Statistical significance was determined by Student's *t*-tests for simple comparison or by one-way ANOVA and Bonferroni multiple comparisons test for multiple comparisons with Graph Pad Prism software. p\<0.05 was considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Smad4 restricts differentiation to promote expansion of satellite cell derived progenitors during muscle regeneration\" for consideration by *eLife*. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, including Amy J Wagers (Reviewer \#1) - who is a member of our Board of Reviewing Editors -- and Colin Crist (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Chakkalakal et al. investigates the impact of deletion of SMAD4, a common signal transducer of the TGFβ superfamily, in adult and aged mouse muscle satellite cells. The authors show that SMAD4 is normally induced during muscle repair in young adults, and furthermore, using well-established lineage-specific, inducible CreER-LoxP deletion strategies, that deletion of Smad4 accelerates satellite differentiation, reduces proliferation, and impairs muscle regeneration after injury. Interestingly, they also examine SMAD4 ablation in aged animals, where it has been suggested that elevated TGFβ signaling constrains robust muscle regenerative potential. Unexpectedly, the authors report impaired SMAD4 induction in aged, regenerating muscle and show that SMAD4 deletion in this context is unable to reverse age-related regenerative defects. These results implicate SMAD4 as a positive regulator of muscle repair, and should prompt additional dissection of the upstream signals that modulate SMAD4 levels during muscle regeneration and aging.

The overall design of this study is straightforward, and should be of interest as it raises new complexities with respect to the interactions of TGF signals and muscle repair. The authors\' use of highly specific genetic systems and aging of their animals out to 2 years is an important contribution. Furthermore, the results nicely highlight important differences in the generative/regenerative responses of developing, adult and aged muscle, and make an important point about the context specificity of SMAD4 requirement and the challenges of predicting pathway activity or impact based solely on ligand levels. However, a major discussion point among the reviewers was the extent to which the work provides new insights into SMAD4 functions, especially as this is a well-studied target in development and skeletal muscle biology, and the extent to which the authors are able to resolve the apparent differences they report between a loss of Smad4 during development, which seems to prevent efficient differentiation but not proliferation, and during adulthood, which reduces proliferation presumably by promoting differentiation. There were also some technical concerns related to the sufficiency with which the authors documented recombination efficiency in their mice, whether Smad4 fails to be upregulated, or if it is already upregulated in satellite cells of aged muscle (the way the data is presented, this is not clear), and whether the defects in P7S4-/- mice persist at later time points after injury. Addressing these points will be essential to shore up the authors\' conclusions, and should be achievable by this team with their existing genetic tools and expertise. If these issues are addressed appropriately, then the work will be appropriate for *eLife*.

Essential revisions:

1\) [Figure 1A, B](#fig1){ref-type="fig"} -- basal levels of SMAD4 protein (in uninjured muscle) seem higher in at least a subset of aged SCs vs. adult SCs. If this is correct it is difficult to interpret the data in [Figure 1C](#fig1){ref-type="fig"}, which expresses data relative to uninjured samples. Thus, for [Figure 1C](#fig1){ref-type="fig"}, quantification and statistics for multiple experiments should be included for comparison of both uninjured and 5dpi to the negative control (not just UI to 5dpi, as currently done). A similar analysis is needed for [Figure 2C](#fig2){ref-type="fig"}. Smad4 and Id1 mRNA expression are likewise not reported for uninjured controls present in [Figure 1D and E](#fig1){ref-type="fig"}, and should be.

2\) The authors need to better assess the SMAD4 deficiency phenotype in satellite cells using additional markers. Pax7 expression alone does not indicate satellite cells undergoing self-renewal. Authors should quantify numbers of Pax7-positive, MyoD-negative verus Pax7-positive, MyoD-positive cells to determine if satellite cells that have not activated the myogenic program are perturbed in their ex vivo culture system. In addition, they should include additional differentiation markers (e.g. myosin heavy chain) to quantify myotube formation and fusion index to support their claim that Smad4 mutant muscle stem cells possess an enhanced propensity for differentiation.

3\) The authors should provide a better evaluation of the efficiency of SMAD4 deletion in the TAM-treated P7S4-/- satellite cells in adult vs. aged mice to verify that deletion efficiency is equivalent at the two ages. If the efficiency of Smad4 gene deletion is low in either circumstance, then it would be necessary to use a recombination sensitive reporter to analyze only cells in which the cre-recombinase was successfully activated, as inclusion of all cells (recombined and not recombined) in the analysis might comprise the results (again, depending on the efficiency of recombination).

4\) In [Figure 8](#fig8){ref-type="fig"}, the authors convincingly demonstrate a reduction in regenerating fiber size at 5dpi in P7S4-/- muscle and aged muscle. Do these defects persist at later timepoints? The authors should examine fiber CSA in more fully regenerated muscle (e.g., 14 and 21 dpi) and in uninjured muscle (at the same post-TAM time point as for the injury/repair studies) as well, to support their conclusions that Smad4-deletion in satellite cells results in severe deficiencies in skeletal muscle regeneration. Both HE and trichrome staining should be shown together with the distribution of fiber sizes. They could also ask if numbers of Pax7-positive cells present underneath the basal lamina return to normal levels in the absence of Smad4, although this might not be testable if they continue to observe a collapse in regeneration at the later timepoint.

5\) The authors need to provide further insight into mechanism to support their conclusion that satellite cell expansion is disrupted with SMAD4 deletion. Inactivation of Smad4 during embryonic development leads to major defects in tongue muscle formation, which was attributed to impaired myogenic differentiation and fusion probably due to decreased expression of FGF4 and FGF6. Thus, the authors should investigate whether the adult phenotype similarly intersects with FGF signaling. To do so, they can use the existing data on tongue muscle development in the NCBI repository, then perform a targeted qPCR panel to identify the suspect FGF factors. The authors can add the suspect FGF exogenously to wt and Smad4 KO satellite cell cultures and ask if the defects they have observed are rescued. This will clarify whether Smad4 targets different pathways during development and adult life, which is a central tenet of the work.
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Author response

*\[...\] Essential revisions:*

*1) [Figure 1A, B](#fig1){ref-type="fig"} -- basal levels of SMAD4 protein (in uninjured muscle) seem higher in at least a subset of aged SCs vs. adult SCs. If this is correct it is difficult to interpret the data in [Figure 1C](#fig1){ref-type="fig"}, which expresses data relative to uninjured samples. Thus, for [Figure 1C](#fig1){ref-type="fig"}, quantification and statistics for multiple experiments should be included for comparison of both uninjured and 5dpi to the negative control (not just UI to 5dpi, as currently done). A similar analysis is needed for [Figure 2C](#fig2){ref-type="fig"}. Smad4 and Id1 mRNA expression are likewise not reported for uninjured controls present in [Figure 1D and E](#fig1){ref-type="fig"}, and should be.*

As requested [Figures 1C](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"} have been modified to include uninjured and 5dpi data. Negative values are subtracted from UI and 5dpi values. Smad4 and Id1 mRNA expression were examined in SCs derived from uninjured adult and aged skeletal muscles. We were unable to obtain consistent Ct values in the detectable range (\< 36) indicative of extremely low/undetectable levels. This is written in the text of the Results (subsection "Smad4 expression is reduced in aged SCs and myogenic cells during regeneration").

*2) The authors need to better assess the SMAD4 deficiency phenotype in satellite cells using additional markers. Pax7 expression alone does not indicate satellite cells undergoing self-renewal. Authors should quantify numbers of Pax7-positive, MyoD-negative verus Pax7-positive, MyoD-positive cells to determine if satellite cells that have not activated the myogenic program are perturbed in their* ex vivo *culture system. In addition, they should include additional differentiation markers (e.g. myosin heavy chain) to quantify myotube formation and fusion index to support their claim that Smad4 mutant muscle stem cells possess an enhanced propensity for differentiation.*

As requested we have conducted assessment of Pax7 and MyoD in our ex vivo culture system, the results are found in [Figure 4C and D](#fig4){ref-type="fig"}, Results (subsection "Smad4 loss severely impairs SC clonal growth and proliferative potential", fourth paragraph). As requested we have conducted myotube formation assays, the results are found in [Figure 3D and E](#fig3){ref-type="fig"}, Results (subsection "Smad4 loss severely impairs SC clonal growth and proliferative potential", second paragraph.

*3) The authors should provide a better evaluation of the efficiency of SMAD4 deletion in the TAM-treated P7S4-/- satellite cells in adult vs. aged mice to verify that deletion efficiency is equivalent at the two ages. If the efficiency of Smad4 gene deletion is low in either circumstance, then it would be necessary to use a recombination sensitive reporter to analyze only cells in which the cre-recombinase was successfully activated, as inclusion of all cells (recombined and not recombined) in the analysis might comprise the results (again, depending on the efficiency of recombination).*

As requested we have examined SMAD4 disruption in P7S4-/- satellite cells, the results are in Figure 8---figure supplement 1. These data indicate similar disruption of SMAD4 in P7S4-/- aged and adult SCs.

*4) In [Figure 8](#fig8){ref-type="fig"}, the authors convincingly demonstrate a reduction in regenerating fiber size at 5dpi in P7S4-/- muscle and aged muscle. Do these defects persist at later timepoints? The authors should examine fiber CSA in more fully regenerated muscle (e.g., 14 and 21 dpi) and in uninjured muscle (at the same post-TAM time point as for the injury/repair studies) as well, to support their conclusions that Smad4-deletion in satellite cells results in severe deficiencies in skeletal muscle regeneration. Both HE and trichrome staining should be shown together with the distribution of fiber sizes. They could also ask if numbers of Pax7-positive cells present underneath the basal lamina return to normal levels in the absence of Smad4, although this might not be testable if they continue to observe a collapse in regeneration at the later timepoint.*

As requested we have conducted experiments to examine regeneration at a later time point. Assessment of H & E and Sirius Red stained sections demonstrate SC specific Smad4 deletion leads to persistent deficiencies in regeneration 14 days after injury regardless of age. These results are found in new [Figure 8](#fig8){ref-type="fig"}, Results (last paragraph). The characterization of sublaminar Pax7 cells in 14 dpi P7S4-/- regenerating skeletal muscles was difficult to assess.

*5) The authors need to provide further insight into mechanism to support their conclusion that satellite cell expansion is disrupted with SMAD4 deletion. Inactivation of Smad4 during embryonic development leads to major defects in tongue muscle formation, which was attributed to impaired myogenic differentiation and fusion probably due to decreased expression of FGF4 and FGF6. Thus, the authors should investigate whether the adult phenotype similarly intersects with FGF signaling. To do so, they can use the existing data on tongue muscle development in the NCBI repository, then perform a targeted qPCR panel to identify the suspect FGF factors. The authors can add the suspect FGF exogenously to wt and Smad4 KO satellite cell cultures and ask if the defects they have observed are rescued. This will clarify whether Smad4 targets different pathways during development and adult life, which is a central tenet of the work.*

As requested we have examined the expression of relevant FGFRs and FGFs pertinent to myogenesis. The results can be found in new [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, Results (subsection "Smad4 loss severely impairs SC clonal growth and proliferative potential", third paragraph), and Discussion (second paragraph). Although similar to the Han et al., 2012 study we do find reduced expression of FGFR4 and FGF6. However, we also observe a reduction in *FGFR1*, no change in FGF1, and a significant induction of FGF2 expression. Although in the Results section (subsection "Smad4 loss severely impairs SC clonal growth and proliferative potential", second paragraph) we only state 10% horse serum, DMEM, in the Materials and methods section under FACs purified SC/MP cultures we state FGF2 was used in our culture system. The latter is correct and we apologize for the confusion this may have caused and corrected the Results section accordingly. Although these data do provide similar results to the tongue study as it pertains to Smad4 loss in myogenic cells leading to decreased FGF6 and FGFR4 expression, the reduction in *FGFR1* and 4, and increased FGF2 expression are not congruent with the notion that FGF supplementation could somehow rescue deficiencies in proliferation. If anything, and consistent with the Han et al., 2012 study, such supplementation may promote terminal commitment. Therefore, based on our observations supplementation of individual FGFs was not conducted.
